These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37990203)

  • 1. Healthcare resource utilization in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD): a real-world data analysis.
    Weiss T; Near AM; Zhao X; Ramey DR; Banerji T; Xie H; Nathan SD
    BMC Pulm Med; 2023 Nov; 23(1):455. PubMed ID: 37990203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of pulmonary hypertension due to chronic obstructive pulmonary disease: Analysis of exacerbations and healthcare resource utilization in the United States.
    Klinger JR; Wu B; Morland K; Classi P; Fiano R; Grabich S
    Respir Med; 2023; 219():107412. PubMed ID: 37729954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excess healthcare resource utilization and costs for commercially insured patients with pulmonary arterial hypertension: A real-world data analysis.
    Weiss T; Ramey DR; Pham N; Shaikh NF; Tian D; Zhao X; Near AM; Lautsch D; Nathan SD
    Pulm Circ; 2024 Apr; 14(2):e12390. PubMed ID: 38903484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
    Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of illness in patients with pulmonary hypertension due to interstitial lung disease: a real-world analysis.
    Heresi G; Dean B; Wu B; Lee H; Sketch MR; Stafkey-Mailey D; Morland K; Classi P; Spikes L
    BMC Pulm Med; 2024 Jul; 24(1):335. PubMed ID: 38992626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population.
    Medrek SK; Sharafkhaneh A; Spiegelman AM; Kak A; Pandit LM
    COPD; 2017 Oct; 14(5):484-489. PubMed ID: 28715281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization.
    Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2409-2421. PubMed ID: 31749614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and Long-Term Impact of Prior Chronic Obstructive Pulmonary Disease Exacerbations on Healthcare Resource Utilization and Related Costs: An Observational Study (SHERLOCK).
    de Nigris E; Haughney J; Lee AJ; Nath M; Müllerová H; Holmgren U; Ding B
    COPD; 2023 Dec; 20(1):92-100. PubMed ID: 36656661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
    Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
    Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
    Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States.
    Sieluk J; Slejko JF; Silverman H; Perfetto E; Mullins CD
    Orphanet J Rare Dis; 2020 Sep; 15(1):260. PubMed ID: 32967697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia.
    Heresi GA; Platt DM; Wang W; Divers CH; Joish VN; Teal SA; Yu JS
    BMC Pulm Med; 2017 Apr; 17(1):58. PubMed ID: 28399914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.